by | Jul 14, 2020 | Dai, Yanan, Fremont, Daved, Harvey, Ian, Nelson, Christopher, Zhao, Haiyan
— A number of bacterial and mammalian expression vectors for production of SARS-CoV proteins that can be used for immunization, B-cell sorting, and human serum evaluation are available.
Expression constructs produce: spike, ACE2, CD147, Surface display, SARS-1 and SARS-2 ORF7a, ORF8, and nucleocapsid…
by | Dec 18, 2019 | Diamond, Michael, Fernandez, Estefania, Fremont, Daved, Nelson, Christopher, Platt, Derek, Zhao, Haiyan
— To generate a panel of antibodies against ZIKV, we serially infected Irf3/ mice 30 days apart with ZIKV MR-766 (Uganda, 1947) and ZIKV H/PF/2013 (French Polynesia, 2013). Irf3/ mice were used instead of wild-type (WT) mice, because ZIKV strains are deficient in evading type I interferon-mediated imm…
by | Oct 22, 2019 | Fremont, Daved, Nelson, Christopher, Teitelbaum, Steven, Warren, Julia
—
Disease indication – Osteoporosis, skeletal metastasis, and potentially rheumatoid arthritis, psoriasis, acute myeloid leukemia, and breast cancer
Drug format – Engineered Protein
Research stage and Preliminary data – Proof of concept in vitro and in vivo
Target – Receptor A…
by | Oct 22, 2019 | Basore, Katherine, Diamond, Michael, Fremont, Daved, Kim, Arthur, Nelson, Christopher, Thackray, Larissa, Zhang, Rong
— Technology Description
Researchers at Washington University in St. Louis have identified a target for therapeutic development and created methods to potentially treat arthritogenic alphavirus infection. Arthritogenic alphaviruses, including chikungunya (CHIKV), Ross River, Mayaro and O’nyong…
by | Oct 22, 2019 | Edelson, Brian, Fremont, Daved, Liu, Chang, Nelson, Christopher, Wang, Xiaoli
— Disease Indications
Drug type: Biologic – engineered protein
Drug class: First in class
Technology:
A recombinant fusion protein that depletes B cells in the recipient that are specific to the donor HLA. The fusion protein offers a targeted therapy for antibody-mediated rejection in the …